UroToday23h
APCCC Diagnostics 2025: What Imaging Should You Use in Case of Suspected Metastases?
For patients with metachronous low burden mCSPC on conventional imaging being recommended for systemic therapy, 51% responded ...
UroToday1d
APCCC Diagnostics 2025: What to Do in Non-Responding PSMA RLT Patients?
APCCC Diagnostics annual meeting featured a session on what we should know for PSMA radioligand therapy and a presentation by ...
UroToday1d
APCCC Diagnostics 2025: Metastatic Disease: Monitoring with Whole Body MRI
APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr.
UroToday2d
APCCC Diagnostics 2025: When to Assess Biology with a Re-Biopsy?
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and ...
UroToday1d
APCCC Diagnostics 2025: When to Assess Biology with ctDNA?
APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr. Alexander Wyatt discussing when we should assess biology with ctDNA. Cell ...
UroToday1d
APCCC Diagnostics 2025: PSA Relapse: When Do You Need to Act?
(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025, held in Lugano, Switzerland, on February 27 th and 28 th, was host to a session addressing the contemporary ...
UroToday1d
APCCC Diagnostics 2025: Genomic Classifiers at the Time of Biochemical Recurrence
(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of biochemically ...
UroToday2d
Leveraging Genomic Insights to Guide Treatment Intensification in Post-Prostatectomy Patients
Phuoc Tran joins Angela Jia to discuss findings from the RTOG 0534 SPPORT trial examining Decipher® genomic classifier scores as predictors of treatment response in post-prostatectomy salvage ...
UroToday6d
Sarcopenia May Increase Cisplatin Toxicity in Bladder Cancer Patients with Borderline Renal Function - Beyond the Abstract
Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy (RC) remains a standard of care treatment for patients with muscle-invasive bladder cancer (MIBC). Cisplatin also figures ...
UroToday5d
Change of the guards-Looking back at Michael Droller: Visionary and supporter-The perspective of the International Bladder Cancer Network.
Professor Michael Droller is stepping down as Editor-in-chief of Urologic Oncology: Seminars and Original Investigations, a journal that he co-founded. This manuscript describes his relation with the ...
UroToday6d
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1-6. However, whether such responses can target cancer driver mutations, lead to immune ...
UroToday6d
VI-RADS-Based Algorithm for Bladder Cancer Management Randomized Retrospective Study - Beyond the Abstract
To evaluate if VI-RADS can distinguish between non-muscle-invasive bladder cancers (NMIBC), muscle-invasive bladder cancer (MIBC), and high-risk non-muscle-invasive bladder cancers (HR-NMIBCs). It is ...